Alamar Biosciences, Inc. (ALMR) FY2026 Q2 P&L / Income Statement

Alamar Biosciences, Inc. (ALMR) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

29,427,000 US dollars

Total cost of revenue

11,709,000 US dollars

Gross profit

17,718,000 US dollars

Total operating expenses

31,250,000 US dollars

Loss from operations

negative 13,532,000 US dollars

Other income (expense), net (calculated)

240,000 US dollars

Net loss before income tax

negative 13,292,000 US dollars

Provision (benefit) for income taxes

negative 93,000 US dollars

Net loss

negative 13,199,000 US dollars

UNITED STATES

19,658,000 US dollars

Europe, Middle East and Africa

6,581,000 US dollars

Asia Pacific

2,685,000 US dollars

Americas (excluding United States)

503,000 US dollars

Research and development

13,817,000 US dollars

Selling, general and administrative

17,433,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.